טוען...
Association with CYP2C19 polymorphisms and Clopidogrel in treatment of elderly stroke patients
BACKGROUND: Clopidogrel is an antiplatelet drug used in the treatment of ischemic stroke. Safety and efficacy of clopidogrel has been confirmed in CAPRIE, PRoFESS trials. However, these studies focused on patients aged less than 75 years. CYP2C19 polymorphisms resulted in individual differences in c...
שמור ב:
| הוצא לאור ב: | BMC Neurol |
|---|---|
| Main Authors: | , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
BioMed Central
2021
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7941922/ https://ncbi.nlm.nih.gov/pubmed/33685396 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12883-021-02127-6 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|